一项研究Osimertinib及Amivantamab在带有常见表皮生长因子受体突变的非小细胞肺癌参与者中的安全性及疗效的研究

排除标准

• Any evidence of diseases, history of allogenic organ transplant, which in the investigator's opinion makes it undesirable for the participant to participate in the study or would jeopardise compliance with protocol.
• Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the osimertinib, or previous significant bowel resection that would preclude adequate absorption distribution, metabolism, or excretion of osimertinib.
• History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥2 years.
• Any unresolved toxicities from prior therapy with Common Terminology Criteria for Adverse Events CTCAE) Grade ≥1, at the time of first dose of study intervention, with the exception of alopecia and Grade 2 prior platinum therapy related neuropathy.
• Spinal cord compression or brain metastases unless asymptomatic, stable, and not requiring corticosteroids for at least 2 weeks prior to start of study intervention.
• Active infection, including tuberculosis and infections with HBV (verified by known positive HBsAg result) or HCV.
• Should participants with HIV infection be included, patients are only eligible if they meet the criteria per protocol.
• Patient with protocol defined cardiac issue.
• History of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD.
• Any concomitant medications known to be associated with Torsade de Pointes.
• Prior exposure to any systemic anti-cancer therapy for advanced NSCLC not amenable to curative surgery or radiation including chemotherapy, biologic therapy, immunotherapy, or any investigational drug.
• Any concurrent anti-cancer treatment without an adequate washout period prior to the first dose of study intervention.
• Palliative radiotherapy with a limited field of radiation within 2 weeks, or with wide field of radiation or to more than 30% of the bone marrow within 4 weeks, prior to the first dose of study intervention.
• Major surgical procedure or significant traumatic injury.
• Current use of medications or herbal supplements known to be strong inducers of CYP 3A4.
• Prior treatment with an EGFR-TKI.
• Participants with a history of hypersensitivity, or intolerance to the active or inactive excipients of osimertinib, amivantamab, or recommended pre-treatments of amivantamab or drugs with a similar chemical structure or class to these drugs.